Payload Information
General Information of This Payload
| Payload ID | PAY0RTKFS |
|||||
|---|---|---|---|---|---|---|
| Name | BCL-xL inhibitor |
|||||
| Synonyms |
BCL-XL inhibitor
Click to Show/Hide
|
|||||
| Target | Bcl-2-like protein 1 (BCL2L1) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
ABBV-637 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Disease control rate (DCR) |
65
73 % |
|||
| Patients Enrolled |
Key eligibility: Adults with solid tumors (Part 1) or EGFR-altered NSCLC (Parts 2-3), measurable disease (RECIST 1.1), ECOG 0-1. Exclusions: cardiac dysfunction (NYHA ≥2 within 6 months), unresolved Grade 2+ toxicities, or (for Part 3) history of ILD/pneumonitis requiring steroids. Requires progression after prior therapies (platinum-based for Part 2, osimertinib for Part 3).
Click to Show/Hide
|
||||
| Administration Dosage |
Participants will receive escalating doses of ABBV-637 in 28-day cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04721015 | Phase Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors
|
||||
| Primary Endpoint |
Primary objectives evaluate safety through AE/SAE incidence (up to 3 years) and efficacy via ORR (confirmed CR/PR per RECIST 1.1 by investigator assessment) in Parts 2 and 3.
|
||||
| Other Endpoint |
Secondary endpoints assess ORR in Part 1 (3 years), DOR (time from CR/PR to progression/death) for ABBV-637 monotherapy (12 months) and combination therapies (20 months), PFS (time to progression/death) and OS (time to death) for docetaxel/osimertinib combinations (20 months).
|
||||
References